Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : EMD Pharmaceuticals, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)

Femme et Homme Max 99 ans
EMD Pharmaceuticals, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany) MAJ Il y a 4 ans

Randomized, phase II, open-label controlled study of two different doses and schedules of EMD 72000 (matuzumab) in combination with pemetrexed, or pemetrexed alone, as second-line treatment in subjects with Stage IIIB/IV non-small cell lung cancer and progressive disease on or after first-line treatment with a platinum analogue in combination with either taxanes, gemcitabine or vinorelbine To determine the tumor response rate (as assessed by the Independent Review Committee [IRC]) of 2 different regimens of matuzumab in combination with pemetrexed in comparison to pemetrexed alone in su...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations